BioTech
Shionogi licenses Pompe disease therapy from Maze Therapeutics
After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.
Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The deal includes additional payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.
Notably, the $150 million upfront is the amount Sanofi was set to pay Maze under an agreement announced last year before it fell apart.
Get unlimited access to award-winning journalism and exclusive events.
